Evidence map›Paper›PMID 40974505›Full record

ArticleEndocrine2025

Follow-up of hypogonadotropic hypogonadism recovery in Chinese male prolactinoma patients treated with dopamine agonists.

Yuanpin Zhang, Yujia Li, Qiaoli Cui, Hangping Zheng, Wanwan Sun, Lili Chen, Xiaoming Zhu, Yiming Li, Hongying Ye, Shuo Zhang and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yuanpin ZhangDepartment of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, 200040, China.
Yujia LiDepartment of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, 200040, China.
Qiaoli CuiDepartment of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, 200040, China.
Hangping ZhengDepartment of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, 200040, China.
Wanwan SunDepartment of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, 200040, China.
Lili ChenDepartment of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, 200040, China.
Xiaoming ZhuDepartment of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, 200040, China.
Yiming LiDepartment of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, 200040, China.
Hongying YeDepartment of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, 200040, China.
Shuo ZhangDepartment of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, 200040, China.
Xiaoxia LiuDepartment of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, 200040, China. xia1119@hotmail.com.
Lijin JiDepartment of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, 200040, China. lijinji@fudan.edu.cn.

Funding

National Natural Science Foundation of China 81800692Noncommunicable Chronic Diseases-National Science and Technology Major Project 2023ZD0506800
6 · The paper itself

Abstract

purposeTo evaluate the prevalence of hypogonadotropic hypogonadism (HH) in male prolactinoma patients with dopamine agonist (DA) therapy and explore the predictive factors of hypogonadism recovery.

designRetrospective study from a single center.

methodsA cohort of male prolactinoma patients who were under medical therapy for at least one year with regular follow-up from the special outpatient clinic in Huashan Hospital was reviewed. Demographic details, clinical features, hormonal profile, medication, imaging characteristics were recorded at diagnosis and during the timeline follow-up.

findingsA total of 73 male prolactinoma patients with median age of 35 (31–51) years old, and BMI of 24.9 ± 2.7 kg/m2 were included. The prevalence of HH at diagnosis was 87.7%. After 2.5 (1.5–3.4) years of DA therapy, 71.4% of HH patients recovered after prolactin normalization. Compared to those with persistent HH, patients with HH recovery had lower baseline BMI (24.2 ± 2.4 vs. 26.4 ± 2.7 kg/m2, p = 0.002), and higher baseline testosterone (4.28 [3.32–6.03] vs. 2.34 [1.36–4.35] nmol/L, p = 0.007). The multivariate logistic regression analysis demonstrated that patients with higher testosterone level (OR 1.679 [1.134–2.487]) or lower BMI (OR 0.761 [0.592–0.977]) at diagnosis had significantly greater possibility of HH recovery, after adjusting for prolactin, adenoma maximal diameter and vision changes.

conclusionsHH is common in male prolactinoma patients and 71.4% of them recovered from HH after prolactin normalization treated by DA. Baseline testosterone and BMI were identified as independent predictors of HH recovery in men with prolactinoma.

Indexed as

Dopamine AgonistsHypogonadismPituitary NeoplasmsProlactinomaAdultBody Mass IndexCabergolineChinaEast Asian PeopleFollow-Up StudiesHumansMaleMiddle AgedRetrospective StudiesTestosteroneCabergolineDopamine AgonistsTestosteroneBMIDopamine receptor agonistsHypogonadotropic hypogonadismProlactinomasTestosterone.

Identifiers

PMID40974505

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.